Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)

Read Full Paperexternally

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Wang et al. (Wed,) studied this question.

synapsesocial.com/papers/69d83979f4e559c61eae3028 https://doi.org/https://doi.org/10.1056/nejmoa1306220

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nonparametric Estimation from Incomplete Observations1958 · 7,764 citations
2Revised Response Criteria for Malignant Lymphoma2007 · 4,443 citations
3Anticoagulation therapy a risk factor for the development of chronic subdural hematoma2012 · 114 citations
4WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues2017 · 13,029 citations
5BTK inhibitor shows positive results in B cell malignancies2012 · 27 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nonparametric Estimation from Incomplete Observations1958 · 7,764 citations
2Revised Response Criteria for Malignant Lymphoma2007 · 4,443 citations
3Anticoagulation therapy a risk factor for the development of chronic subdural hematoma2012 · 114 citations
4WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues2017 · 13,029 citations
5BTK inhibitor shows positive results in B cell malignancies2012 · 27 citations